Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Subst Abus. 2012;33(1):48-59. doi: 10.1080/08897077.2011.609438.

A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers.

Author information

  • 1University of Pennsylvania, Philadelphia, Pennsylvania, USA. coviello d@mail.trc.upenn.edu


A feasibility study was conducted to pilot test the ability of 5 sites to recruit, treat, and retain opioid-dependent offenders in a trial of extended-release injectable naltrexone (XR-NTX). The participants, 61 previously opioid-dependent individuals under legal supervision in the community, received up to 6 monthly injections of Depotrex brand naltrexone and completed a 6-month follow-up interview. Six-month outcomes showed that those who completed treatment had significantly fewer opioid-positive urines and were less likely to have been incarcerated than those who had not completed treatment. The findings indicate that XR-NTX holds promise as a feasible, effective treatment option for opioid-dependent offenders.

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon Icon for PubMed Central
    Loading ...
    Write to the Help Desk